Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.61 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | CD44 | P16070 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2258194 | 0.98 | PNMT (0.59) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL14692360 | 0.89 | PNMT (0.50) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL327075 | 0.84 | CD44 (0.61) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL29587158 | 0.84 | CD44 (0.61) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL16518079 | 0.84 | PRCP (0.61) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL16518013 | 0.83 | PRCP (0.59) | PNMTPRCPCD44MAOBADRA2A | |
| Hydrochloric Acid SCHEMBL1124513 | 0.82 | CD44 (0.59) | PNMTPRCPCD44MAOBADRA2A | |
| Hydrochloric Acid SCHEMBL29586475 | 0.82 | CD44 (0.59) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL330078 | 0.81 | CD44 (0.42) | PNMTPRCPCD44MAOBADRA2A | |
| SCHEMBL29972587 | 0.81 | CD44 (0.42) | PNMTPRCPCD44MAOBADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4737504-A | INCREASE BETA-2 ADRENERGIC ACTIVITY WHILE DECREASING BETA-1; CARDIOVASCULAR AND RESPIRATORY DISORDERS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-04-12 | — | — | US | claimed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3768671-B1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-05-22 | — | — | EP | disclosed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| CN-106103426-A | 8 (piperazine 1 base) 1,2,3,4 tetrahydro isoquinoline derivatives | 埃科特莱茵药品有限公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| CN-104011021-A | Heterocyclic derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD | 2014-08-27 | — | — | CN | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-0906283-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | PNMT 3156/4885PRCP 3251/4885CD44 4088/4885 |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | PNMT 2800/4885PRCP 1601/4885CD44 958/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PNMT 4852/4885PRCP 1983/4885CD44 3337/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | PNMT 559/4885PRCP 2970/4885CD44 4637/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | PNMT 364/4885PRCP 2104/4885CD44 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.